肝硬化患者肠道微生物组抗生素耐药基因负荷对临床结局的影响
本研究在163例肝硬化门诊患者和40例对照中分析肠道宏基因组抗生素耐药基因(ARG)丰度变化及其对90天住院和1年死亡的多变量影响,并在19例代偿期肝硬化患者中开展利福昔明开放标签试验,同时用机器学习比较肝硬化与慢性肾脏病和糖尿病的ARG模式。结果显示肝硬化患者ARG丰度高于对照、随疾病严重程度加重而升高,且与住院和死亡相关,利福昔明对ARG模式影响甚微。
要点
- 肝硬化患者肠道ARG丰度高于对照,并随肝硬化严重程度加重而升高。
- ARG丰度与90天住院和1年死亡相关,校正并发症、用药和人口学后仍显著。
- 利福昔明治疗8周后ARG丰度模式变化甚微。
核心结论
- 肝硬化与肠道微生物ARG高负荷相关,ARG负荷随疾病进展加重,且与住院和死亡相关,利福昔明不影响ARG。
研究设计与样本
- 纳入163例肝硬化门诊患者(43例代偿期、20例仅腹水、30例仅肝性脑病、70例两者兼有)和40例对照进行宏基因组分析。
- 在19例代偿期肝硬化患者中开展开放标签试验,比较利福昔明治疗前与治疗8周后的ARG。
- 将慢性肾脏病和糖尿病研究中的ARG与肝硬化通过机器学习进行比较。
主要发现
- 肝硬化患者ARG丰度高于对照,并随肝硬化严重程度加重而升高。
- 随访期间44例住院、14例死亡,ARG丰度与住院和死亡相关,校正肝硬化并发症、用药和人口学特征后仍显著。
- 利福昔明治疗8周后19例患者ARG丰度模式变化甚微。
- 机器学习可区分肝硬化与慢性肾脏病和糖尿病的ARG模式,肝硬化包含更多革兰阳性菌ARG。
临床怎么用
- 肝硬化患者肠道ARG负荷高且随病情加重,可提示住院和死亡风险。
- 利福昔明对肠道ARG负荷影响甚微,不应以降低ARG为目的使用。
局限性
- 利福昔明试验为开放标签设计,样本量仅19例。
- 研究为观察性设计,ARG与结局的关联不能证明因果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Cirrhosis is associated with changes in intestinal microbiota that can lead to hepatic encephalopathy (HE) and infections, especially with antibiotic-resistant organisms. However, the impact of gut microbial antibiotic resistance gene (ARG) burden on clinical outcomes is unclear. The aims of the study were to determine the impact of ARGs in cirrhosis-related gut metagenome on outcomes and disease progression, study the effect of rifaximin on ARG burden, and compare ARGs in cirrhosis with chronic kidney disease (CKD) and diabetes. METHODS: In outpatients with cirrhosis who underwent metagenomics, we evaluated change in ARG abundances with progression and their multivariable impact on 90-day hospitalizations and deaths over 1 year. We also studied ARGs pre- and 8 weeks post-rifaximin in patients with compensated cirrhosis in an open-label trial. Finally, ARGs from CKD and diabetes studies were compared with cirrhosis on machine learning. RESULTS: A total of 163 patients with cirrhosis (43 compensated, 20 ascites-only, 30 HE-only, 70 both) and 40 controls were included. ARG abundances were higher in cirrhosis versus controls and worsened with advancing cirrhosis severity; 44 patients were hospitalized and 14 died. ARG abundances were associated with hospitalizations and mortality while controlling for cirrhosis complications, medications, and demographics. Rifaximin trial: ARG abundance patterns were minimally affected in 19 patients post-rifaximin. CKD/diabetes comparison: ARG abundance patterns in cirrhosis are distinguishable on machine learning and include more gram-positive ARGs. CONCLUSIONS: Cirrhosis is associated with high gut microbial ARG gene burden compared with controls, which worsens with disease progression and may be different from CKD and diabetes. ARGs are not affected by rifaximin and are associated with hospitalizations and death.
引用
- Shamsaddini A, Gillevet PM, Acharya C, et al. Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis. Gastroenterology. 2021. PMID: 33857456. doi:10.1053/j.gastro.2021.04.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。